BR112022017973A2 - Imunização de reforço ativa contra tétano, difteria e coqueluche - Google Patents

Imunização de reforço ativa contra tétano, difteria e coqueluche

Info

Publication number
BR112022017973A2
BR112022017973A2 BR112022017973A BR112022017973A BR112022017973A2 BR 112022017973 A2 BR112022017973 A2 BR 112022017973A2 BR 112022017973 A BR112022017973 A BR 112022017973A BR 112022017973 A BR112022017973 A BR 112022017973A BR 112022017973 A2 BR112022017973 A2 BR 112022017973A2
Authority
BR
Brazil
Prior art keywords
diphtheria
immunization against
against tetanus
wholesome
boost immunization
Prior art date
Application number
BR112022017973A
Other languages
English (en)
Inventor
d campbell John
L Coffman Robert
N Hyer Randall
S Janssen Robert
Novack David
Gohlke Martin
Urban Maureen
Gairola Sunil
Shaligram Umesh
Gautum Manish
Rao Harish
Original Assignee
Dynavax Tech Corp
Serum Institute Of India Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dynavax Tech Corp, Serum Institute Of India Pvt Ltd filed Critical Dynavax Tech Corp
Publication of BR112022017973A2 publication Critical patent/BR112022017973A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0016Combination vaccines based on diphtheria-tetanus-pertussis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/08Clostridium, e.g. Clostridium tetani
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/05Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/099Bordetella
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/125Picornaviridae, e.g. calicivirus
    • A61K39/13Poliovirus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5252Virus inactivated (killed)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55561CpG containing adjuvants; Oligonucleotide containing adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/17Immunomodulatory nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/315Phosphorothioates
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

IMUNIZAÇÃO DE REFORÇO ATIVA CONTRA TÉTANO, DIFTERIA E COQUELUCHE. A presente invenção refere-se a composições imunogênicas compreendendo antígenos de tétano, difteria e coqueluche acelular (Tdap), e um agonista do receptor 9 do tipo toll (TLR9), tal como oligonucleotídeo compreendendo um motivo de citidina-fosfo-guanosina (CpG) não metilado. As composições imunogênicas podem ainda compreender um adjuvante sal de alumínio ao qual os antígenos de Tdap são adsorvidos. As composições imunogênicas são adequadas para imunização de reforço ativa contra tétano, difteria e coqueluche em um indivíduo em necessidade das mesmas.
BR112022017973A 2020-03-09 2021-03-09 Imunização de reforço ativa contra tétano, difteria e coqueluche BR112022017973A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN202011010025 2020-03-09
IN202011055399 2020-12-19
PCT/US2021/021532 WO2021183533A1 (en) 2020-03-09 2021-03-09 Active booster immunization against tetanus, diphtheria and pertussis

Publications (1)

Publication Number Publication Date
BR112022017973A2 true BR112022017973A2 (pt) 2022-11-16

Family

ID=77672117

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022017973A BR112022017973A2 (pt) 2020-03-09 2021-03-09 Imunização de reforço ativa contra tétano, difteria e coqueluche

Country Status (12)

Country Link
US (1) US20230072809A1 (pt)
EP (1) EP4117719A4 (pt)
JP (1) JP2023517330A (pt)
KR (1) KR20230011916A (pt)
CN (1) CN115697389A (pt)
AU (1) AU2021236055A1 (pt)
BR (1) BR112022017973A2 (pt)
CA (1) CA3174987A1 (pt)
CL (1) CL2022002456A1 (pt)
IL (1) IL296286A (pt)
MX (1) MX2022011155A (pt)
WO (1) WO2021183533A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115554395A (zh) * 2022-10-12 2023-01-03 长春百克生物科技股份公司 一种百白破复合佐剂联合疫苗

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060014713A1 (en) * 2004-06-15 2006-01-19 Hybridon, Inc. Immunostimulatory oligonucleotide multimers
EP1979488A4 (en) * 2006-01-09 2009-05-27 Univ California IMMUNOSTIMULATORY COMBINATIONS OF TNFRSF, TLR, NLR, RHR, PURINERGIC RECEPTOR AND CYTOKINE RECEPTOR AGONISTS USED FOR VACCINES AND ANTI-TUMOR IMMUNOTHERAPY
US9254327B2 (en) * 2010-05-10 2016-02-09 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
US9452212B2 (en) * 2011-04-14 2016-09-27 Dynavax Technologies Corporation Methods and compositions for eliciting an immune response against hepatitis B virus
DK2863943T3 (en) * 2013-03-08 2016-11-07 Janssen Vaccines & Prevention Bv acellular pertussis vaccines
AU2014304545A1 (en) * 2013-08-05 2016-02-25 Glaxosmithkline Biologicals S.A. Combination immunogenic compositions
CN113395977A (zh) * 2018-12-05 2021-09-14 圣诺菲·帕斯图尔公司 百日咳加强疫苗

Also Published As

Publication number Publication date
CN115697389A (zh) 2023-02-03
EP4117719A4 (en) 2024-05-22
WO2021183533A1 (en) 2021-09-16
AU2021236055A1 (en) 2022-10-20
US20230072809A1 (en) 2023-03-09
CL2022002456A1 (es) 2023-06-23
CA3174987A1 (en) 2021-09-16
JP2023517330A (ja) 2023-04-25
IL296286A (en) 2022-11-01
KR20230011916A (ko) 2023-01-25
MX2022011155A (es) 2023-01-04
EP4117719A1 (en) 2023-01-18

Similar Documents

Publication Publication Date Title
AU2017200312B2 (en) Vaccines with higher carbohydrate antigen density and novel saponin adjuvant
CY1118629T1 (el) Εμβολιο ιου ερπητα ζωστηρα
CL2020001478A1 (es) Composiciones que comprenden conjugados de polisacárido de streptococcus pneumoniae con proteína y métodos de uso de estos.
NZ596870A (en) Vaccine compositions comprising a saponin adjuvant
SG162818A1 (en) Multivalent entrain-and-amplify immunotherapeutics for carcinoma
RU2016109925A (ru) Адъюванты на масляной основе
AR053711A1 (es) Combinacion de vacunas para circovirus porcina y helicobacter y metodos de utilizacion
BRPI0620193B8 (pt) composição imunogênica e vacina a compreendendo, bem como processo para preparar a vacina
GB201101665D0 (en) Immunogenic compositions
PE20020126A1 (es) Composicion de vacuna
WO2006060710A3 (en) Vaccine formulations for intradermal delivery comprising adjuvants and antigenic agents
CO6331297A2 (es) Composiciones adyuvantes novedosas
BRPI0510570A (pt) composição de vacina
WO2005016239A3 (en) Molecules enhancing dermal delivery of influenza vaccines
BR112022017973A2 (pt) Imunização de reforço ativa contra tétano, difteria e coqueluche
AR092896A1 (es) Composiciones inmunogenicas
BR112015005056A2 (pt) vacinas de combinação com sorogrupo b meningococcus e d/t/p
BR0212556A (pt) interleucina-12 como um adjuvante de vacina veterinária
BR112015021523A2 (pt) composição de uma vacina contra a tosse convulsa acelular, e, métodos para vacinar um sujeito contra a bordetella pertussis e para proteger um sujeito da tosse convulsa
CA2646574A1 (en) Vaccine against mycoplasma and prrsv
AR088907A1 (es) Vacuna
BR0111834A (pt) Composições adjuvante e imunogênica, e, método para eliciar uma resposta imune a um antìgeno
EP4248992A3 (en) Foot-and-mouth disease vaccine
MX2022010642A (es) Vacunas contra coronavirus que comprenden un agonista de tlr9.
GB2444676A (en) Adjuvanted vaccine